| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.6M | — | -26.0% |
| SG&A Expense | $6.8M | — | +17.4% |
| Operating Income | -$8.4M | — | -5.6% |
| Net Income | -$12.8M | — | -2349.6% |
| EPS (Basic) | -$0.54 | — | -1450.0% |
| EPS (Diluted) | -$0.54 | — | -980.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $37.4M | +28.0% | +89.0% |
| Short-term Investments | $17.2M | +42.6% | — |
| Current Assets | $63.5M | +29.8% | +132.4% |
| Total Assets | $64.4M | +31.1% | +130.5% |
| Current Liabilities | $26.5M | +39.9% | +58.8% |
| Total Liabilities | $26.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.2M | — | +29.9% |
| Capital Expenditures | $8K | — | -50.0% |
| Investing Cash Flow | -$5.2M | — | — |
| Financing Cash Flow | $19.6M | — | +668.6% |
| Free Cash Flow | -$6.2M | — | +29.9% |
| +60.1% |
| Stockholders' Equity | $37.7M | +24.9% | +234.5% |